NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)

The National Institutes of Health, through the National Heart, Lung, and Blood Institute (NHLBI), invites applications under the NHLBI Trans-Omics for Precision Medicine (TOPMed) program for omics phenotypes of heart, lung, and blood disorders. This opportunity provides access to NHLBI-funded resources to generate large-scale integrated genetic and multi-omics data that advance the understanding of molecular mechanisms underlying Heart, Lung, Blood, and Sleep (HLBS) disorders. This solicitation is issued as an X01 Resource Access Award and does not provide direct funding. Instead, successful applicants will gain access to TOPMed omics data generation services to support research designed to uncover mechanistic and molecular drivers of HLBS diseases. NHLBI established TOPMed to integrate genetic, molecular, and clinical data from diverse cohorts in order to translate genetic discoveries into insights that inform prevention, diagnosis, and treatment. This reissued NOFO (PAR-25-447) continues that mission by enabling researchers to access sequencing, epigenomic, transcriptomic, metabolomic, proteomic, and single-cell omics services. The data produced will be harmonized through NHLBI-designated informatics centers and shared publicly via databases such as dbGaP and BioData Catalyst, in accordance with the NIH Genomic Data Sharing Policy. The initiative encourages applicants to propose studies that fill scientific gaps, particularly in rare or underrepresented HLBS conditions like sickle cell disease, peripartum cardiomyopathy, and interstitial lung disease. Applications must demonstrate high-quality, well-characterized biospecimens suitable for the requested omics assays. Projects should include a clear rationale for data types requested, describe existing and complementary phenotypic data, and outline how proposed datasets will enrich TOPMed’s existing collection of over 200,000 whole genome sequences. Applicants must consent to data-sharing, ensure appropriate IRB oversight, and commit to participating in the TOPMed consortium’s collaborative framework. Foreign organizations and non-domestic components of U.S. entities are eligible, provided they comply with NIH data policies. Applications are submitted electronically through ASSIST, Grants.gov Workspace, or approved institutional systems. No letter of intent is required. The next application due date is November 6, 2025, with additional recurring deadlines in February, June, and October through May 2028. Review follows standard NIH peer review processes assessing significance, investigator qualifications, innovation, approach, and environment. Reviewers will evaluate the need for omics access, data-sharing plans, biospecimen quality, and scientific merit. Up to ten projects may be approved each cycle, with a maximum project period of three years. Successful applicants will not receive a Notice of Award but will instead be granted access to TOPMed resources. Administrative and ethical approvals must be in place prior to data generation. Questions may be directed to the NHLBI Division of Blood Diseases and Resources at nhlbidbdrgrantresource@nhlbi.nih.gov, or program officers Jane Ye, Ph.D. (jane.ye@nih.gov, 301-480-7447) and Ye Yan, Ph.D. (ye.yan@nih.gov, 301-480-6779). This NOFO is authorized under Sections 301 and 405 of the Public Health Service Act (42 USC 241 and 284) and governed by 42 CFR Part 52 and 2 CFR Part 200.

Apply early to allow time for corrections. Ensure biospecimens are well-characterized. Contact NHLBI staff to confirm alignment with program scope and assay capabilities